Share This Article:

Study of negatives symptoms in first episode schizophrenia

Abstract Full-Text HTML XML Download Download as PDF (Size:74KB) PP. 323-328
DOI: 10.4236/ojpsych.2013.33033    3,879 Downloads   5,934 Views   Citations

ABSTRACT

Background: Prevalence of negative symptoms in the early phase of schizophrenia remains uncertain. Negative symptoms are the primary cause of long term disability and poor functional outcome. The purpose of this study is to examine the presence of negative symptoms in patients with fist episode psychosis in schizophrenia who were hospitalized. Methods: Negative symptoms were measured in 72 patients presenting with FEP using the scale for assessment of negative symptoms (SANS) and ascertained diagnosis using DSM-IV. Prevalence of SANS items and subscales were examined for both schizophrenia and bipolar disorder. Results: This study shows that a significant number of patients with first episode schizophrenia had negative symptoms 66 (87.5%). All five subtypes of negative symptoms were present in 47% of patients suggesting primary negative symptoms, and about 40% have secondary negative symptoms. Independently, each subtype of negative symptoms was seen in 48% - 76% of patients. The most prevalent negative symptom in first-episode schizophrenia was found to be blunting (72%). 46% of patients had significant level of depression, overall psychopathology was severe and level of functioning was poor. We found that 45.8% patients were prescribed anticholinergic medications which indicated that at least 45% subjects had extra-pyramidal symptoms (EPS). Conclusion: Primary negative symptoms are prevalent in about half of First episode Psychosis (FEP) schizophrenia patients. These findings have implications for identification, early treatment, and reduced treatment resistance for negative symptoms in order to increase social and clinical outcome of schizophrenia. Further research is required in this area.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Bambole, V. , Shah, N. , Sonavane, S. , Johnston, M. and Shrivastava, A. (2013) Study of negatives symptoms in first episode schizophrenia. Open Journal of Psychiatry, 3, 323-328. doi: 10.4236/ojpsych.2013.33033.

References

[1] Makinen, J., Miettunen, J., Isohanni, M. and Koponen, H. (2008) Negative symptoms in schizophrenia: A review. Nordic Journal of Psychiatry, 62, 334-341. doi:10.1080/08039480801959307
[2] Amminger, G.P., Henry, L.P., Harrigan, S.M., et al. (2011) Outcome in early-onset schizophrenia revisited: Findings from the Early Psychosis Prevention and Intervention Centre long-term follow-up study. Schizophrenia Research, 131, 112-119. doi:10.1016/j.schres.2011.06.009
[3] Shrivastava, A., Johnston, M., Thakar, M., Stitt, L. and Shah, N. (2011) Social outcome in clinically recovered first-episodeschizophrenia in a naturalistic, ten-year, follow-up study in India. Clinical Schizophrenia & Related Psychoses, 5, 95-101. doi:10.3371/CSRP.5.2.6
[4] Miller, D., Perry, P., Cadoret, R. and Andreasen, N. (1994) Clozapine’s effect on negative symptoms in treatment-refractory schizophrenia. Comprehensive Psychiatry, 35, 8-15. doi:10.1016/0010-440X(94)90164-3
[5] Tandon, R., Nasrallah, H.A. and Keshavan, M.S. (2009) Schizophrenia, “just the facts”: Clinical features and conceptualization. Schizophrenia Research, 110, 1-23. doi:10.1016/j.schr es.2009.03.005
[6] Greenwood, K.E., Landau, S. and Wykes, T. (2005) Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy. Schizophr Bull, 31, 910-921. doi:10.1093/schbul/sbi035
[7] Bobes, J., Arango, C., Garcia-Garcia, M. and Rejas, J. (2010) Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. Journal of Clinical Psychiatry, 71, 280-286. doi:10.4088/JCP.08m04250yel
[8] Gardner, K.N. and Bostwick, J.R. (2012) Antipsychotic treatment response in schizophrenia. American Journal of Health-System Pharmacy, 69, 1872-1890. doi:10.2146/ajhp110559
[9] Gupta, S., Andreasen, N.C., Arndt, S., et al. (1997) The Iowa longitudinal study of recent onset psychosis: Oneyear follow-up of first episode patients. Schizophrenia Research, 23, 1-13. doi:10.1016/S0920-9964(96)00078-3
[10] Wood, S., Nelson, B., Brewer, W., et al. (2011) Neurocognitive predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosis. Schizophrenia Research, 132, 1-7. doi:10.1016/j.schres.2011.06.014
[11] Addington, J., Leriger, E. and Addington, D. (2003) Symptom outcome 1 year after admission to an early psychosis program. Canadian Journal of Psychiatry, 48, 204-207.
[12] Husted, J.A., Beiser, M. and Iacono, W.G. (1995) Negative symptoms in the course of first episode affective psychosis. Psychiatry Research, 56, 145-154. doi:10.1016/0165-1781(94)02576-X
[13] Hovington, C. and Lepage, M. (2012) Neurocognition and neuroimaging of persistent negative symptoms of schizophrenia. Expert Review of Neurotherapeutics, 12, 53-69. doi:10.1586/ern.11.173
[14] Nejad, A., Madsen, K., Ebdrup, B., et al. (2011) Neural markers of negative symptom outcomes in distributed working memory brain activity of antipsychotic-naive schizophrenia patients. The International Journal of Neuropsychopharmacology, 14, 69-82.
[15] Lyne, J., O’Donoghue, B., Owens, E., Renwick, L., et al. (2012) Prevalence of item level negative symptoms in first episode psychosis diagnoses. Schizophrenia Research, 135, 128-133. doi:10.1016/j.schres.2012.01.004
[16] O’Donoghue, B., Owens, E., Renwick, L., et al. (2012) Prevalence of item level negative symptoms in first episode psychosis diagnoses. Schizophrenia Research, 135, 128-133. doi:10.1016/j.schres.2012.01.004
[17] Thaker, G.K. (2007) Schizophrenia endophenotypes as treatment targets. Expert Opinion on Therapeutic Targets, 11, 1189-1206. doi:10.1517/14728222.11.9.1189
[18] American Psychiatric Association (1994) DSM-IV: Diagnostic and statistical manual of mental disorders. 4th Edition, APA, Washington, DC.
[19] Andreasen, N.C. (1983) Scale for Assessment of Negative Symptoms (SANS). University of Iowa Press, Iowa City.
[20] Hamilton, M. (1960) A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry, 23, 56-62. doi:10.1136/jnnp.23.1.56
[21] Guy, W. (1976) Clinical Global Impression (CGI) ECDEU assessment manual for psychopharmacology. US Department of Health, Rockville.
[22] Peralta, V., Cuesta, M., Martinez-Larrea, A., et al. (2000) Differentiating primary from secondary negative symptoms in schizophrenia: A study of neuroleptic-naive patients before and after treatment. American Journal of Psychiatry, 157, 1461-1466. doi:10.1176/appi.ajp.157.9.1461
[23] Lindenmayer, J.P., Bossie, C.A., Kujawa, M., et al. (2008) Dimensions of psychosis in patients with bipolar mania as measured by the positive and negative syndrome scale. Psychopathology, 41, 264-270.
[24] Chang, W., Christy, L., Jennifer, Y., et al. (2011) Persistent negative symptoms in first-episode schizophrenia: A prospective three-year follow-up study. Schizophrenia Research, 133, 22-28. doi:10.1016/j.schres.2011.09.006
[25] Galderisi, S., Mucci, A., Bitter, I., et al. (2012) Persistent negative symptoms in firstepisode patients with schizophrenia: Results from the European FirstEpisodeSchizophrenia Trial. European Neuropsychopharmacology, 12, 224-232.
[26] Suzuki, T., Remington, G., Mulsant, B.H., et al. (2012) Defining treatment resistant schizophrenia and response to antipsychotics: A review and recommendation. Psychiatry Research, 197, 28-33. doi:10.1016/j.psychres.2012.02.013
[27] Makinen, J., Miettunen, J., Jaaskelainen, E., et al. (2010) Negative symptoms and their predictors in schizophrenia within the Northern Finland 1966 Birth Cohort. Psychiatry Research, 178, 121-125. doi:10.1016/j.psychres.2009.05.011
[28] Hovington, C.L., Bodnar, M. and Joober, R. (2012) Identifying persistent negative symptoms in first episode psychosis. BMC Psychiatry, 12, 224. doi:10.1186/1471-244X-12-224
[29] Bobes, J., Arango, C., Garcia-Garcia, M., et al. (2010) Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: Findings from the CLAMORS study. Journal of Clinical Psychiatry, 71, 280-286. doi:10.4088/JCP.08m04250yel
[30] Chang, W.C., Hui, C.L., Tang, J.Y., et al. (2012) Impacts of duration of untreated psychosis on cognition and negative symptoms in first-episode schizophrenia: A 3-year prospective follow-up study. Psychological Medicine, 1-11. doi:10.1017/S0033291712002838
[31] Boonstra, N., Klaassen, R. and Sytema, S. (2012) Duration of untreated psychosis and negative symptoms—A systematic review and meta-analysis of individual patient data. Schizophrenia Research, S0920-9964(12)00498-7.
[32] Cullen, K., Guimaraes, A., Wozniak, J., et al. (2011) Trajectories of social withdrawal and cognitive decline in the schizophrenia prodrome. Clinical Schizophrenia & Related Psychoses, 4, 229-238. doi:10.3371/CSRP.4.4.3
[33] Klaassen, R.M., Velthorst, E., Nieman, D.H., et al. (2011) Factor analysis of the scale of prodromal symptoms: Differentiating between negative and depression symptoms. Psychopathology, 44, 379-385. doi:10.1159/000325169
[34] Lin, A., Wood, S.J., Nelson, B., et al. (2011) Neurocognitive predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosis. Schizophrenia Research, 132, 1-7. doi:10.1016/j.schres.2011.06.014
[35] Gee, D.G. and Cannon, T.D. (2011) Prediction of conversion to psychosis: Review and future directions. Revista Brasileira de Psiquiatria, 33, 129-142.
[36] Sommer, I.E., Begemann, M.J., Temmerman, A., et al. (2012) Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull, 38, 1003-1011. doi:10.1093/schbul/sbr004
[37] Zink, M., Englisch, S. and Meyer-Lindenberg, A. (2011) Polypharmacy in schizophrenia. Nervenarzt, 82, 853-858. doi:10.1007/s00115-010-3196-0
[38] Englisch, S. and Zink, M. (2012) Treatment-resistant schizophrenia: Evidence-based strategies. Mens Sana Monographs, 10, 20-32. doi:10.4103/0973-1229.91588
[39] Himelhoch, S., Slade, E., Kreyenbuhl, J., et al. (2012) Antidepressant prescribing patterns among VA patients with schizophrenia. Schizophrenia Research, 136, 32-35. doi:10.1016/j.schres.2012.01.008
[40] Premkumar, T.S. and Pick, J. (2006) Lamotrigine for schizophrenia. Cochrane Database of Systematic Reviews, 4, CD005962.
[41] Murphy, B.P., Chung, Y.C., Park, T.W., et al. (2006) Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review. Schizophrenia Research, 88, 5-25. doi:10.1016/j.schres.2006.07.002
[42] Fakra, E. and Azorin, J.M. (2012) Clozapine for the treatment of schizohrenia. Expert Opinion on Pharmacotherapy, 13, 1923-1935. doi:10.1517/14656566.2012.709235
[43] Vera, I., Rezende, L., Molina, V., et al. (2012) Clozapine as treatment of first choice in first psychotic episodes. What do we know? Actas Espa?olas de Psiquiatría, 40, 281-289.
[44] Moore, T.A., Buchanan, R.W., Buckley, P.F., et al. (2007) The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. Journal of Clinical Psychiatryiatry, 68, 1751-1762. doi:10.4088/JCP.v68n1115
[45] Levine, S.Z. and Leucht, S. (2013) Attaining and sustaining remission of predominant negative symptoms. Schizophrenia Research, 143, 60-64. doi:10.1016/j.schres.2012.11.010
[46] Herbener, E.S. and Harrow, M. (2001) Longitudinal assessment of negative symptoms inschizophrenia/schizoaffective patients, other psychotic patients, and depressedpatients. Schizophr Bull, 27, 527-537. doi:10.1093/oxfordjournals.schbul.a006893

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.